DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Anagliptin
Anagliptin
Computationally Guided Design of Dipeptidyl Peptidase-4 Inhibitors Lauren C
200 Adverse Drug Reactions in a Southern Hospital in Taiwan 201
CDR Clinical Review Report for Soliqua
Comparison of Clinical Outcomes and Adverse Events Associated with Glucose-Lowering Drugs in Patients with Type 2 Diabetes: a Meta-Analysis
Estimation of Anagliptin and Metformin HCI in Bulk
WHO Drug Information Vol
Essential Medicines List (EML) 2017 Application for the Revision Of
Anagliptin Monotherapy in Patients with Type 2 Diabetes Mellitus and High Low-Density
Treatment with DPP-4I Anagliptin Or A-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats
Anagliptin Ameliorates Albuminuria and Urinary Liver-Type Fatty Acid
Beneficial Effect of Anti-Diabetic Drugs for Nonalcoholic Fatty Liver Disease
Oral Anti-Diabetic Agents-Review and Updates
Stembook 2018.Pdf
Unintended Effects of Anti-Hyperglycaemic Drugs Studied in Population-Based Cohorts
The Effects of Teneligliptin on Lipid Profile: a Prospective Study for Comparison of Biomarkers Before and After a Meal
2020 Diabetes Guideline Data Supplement
NLRP3 Inflammasome in Endothelial Dysfunction
Summary of Investigation Results Anagliptin, Linagliptin, Teneligliptin Hydrobromide Hydrate, and Teneligliptin Hydrobromide Hydrate/Canagliflozin Hydrate
Top View
(12) United States Patent (10) Patent No.: US 9,694,053 B2 Haack Et Al
HOULUTUULLITTURUS009789165B2 (12 ) United States Patent (10 ) Patent No
Product List
Pharmaceutical Composition for Preventing Or Treating Diabetes, Containing Zinc Salt, Cyclo-Hispro and Antidiabetic Drug As Active Ingredients
Targets and Off-Targets of Kinase Inhibitors in Diabetes
Data Supplement
VA/Dod CLINICAL PRACTICE GUIDELINE for the MANAGEMENT of CHRONIC KIDNEY DISEASE
453 Chronic Treatment with Anagliptin, a Dipeptidyl
Density Lipoprotein Cholesterol in Diabetes
Linagliptin for the Treatment of Type 2 Diabetes
Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors
Complete Dissertation
Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia
Dipeptidyl Peptidase 4 Inhibitors for The
Preparation on Sustained-Release Drug of Na-MMT-Miglitol
Renoprotective Effects of DPP-4 Inhibitors
Modern Management of Diabetes Mellitus Case 1 Case 2 Case 3
Spectrophotometric Method Development and Validation for Anagliptin and Metformin Hcl by Simultaneous Equation Method in Synthetic Mixture”
Download the Poster Abstracts
Pharmacotherapeutics of Miglitol: an Α-Glucosidase Inhibitor
2019 Medicines in Development for Diabetes and Related Conditions
Endocrinology) Meeting Deliberated the Proposals on 22-03-2016 and Recommended the Following
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Overview of Type 2 Diabetes Drugs on the Market
Pharmacologically Relevant Drug Interactions of Α-Glucosidase Inhibitors
Development and Validation of Rapid RP-HPLC and Green Second
Biocatalyzed Synthesis of Antidiabetic Drugs: a Review
Article Download
Treatment with Anagliptin, a DPP-4 Inhibitor, Decreases FABP4
History of Glucose-Lowering Agent Development
Lowering Drugs on Body Weight in People with Type 1 Diabetes: a Systematic Review and Network Meta-Analysis Protocol
High-Fat Diet Feeding Significantly Attenuates Anagliptin-Induced
Anagliptin Ameliorates High Glucose- Induced Endothelial Dysfunction Via
SUINY Tablets 100Mg
Identification and Characterization of Antidiabetic And
W J C C Clinical Cases
Efficacy of Anagliptin As Compared to Linagliptin on Metabolic Parameters Over 2 Years of Drug Consumption: a Retrospective Cohort Study
2016 Medicines in Development for Diabetes and Related Conditions
An Integrated in Silico and in Vitro Assays of Dipeptidyl Peptidase-4 and Α-Glucosidase Inhibition by Stellasterol from Ganoderma Australe
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Possibility of Pharmacokinetic Drug Interaction Between a DPP-4 Inhibitor and a SGLT2 Inhibitor
WO 2017/198177 Al 23 November 2017 (23.11.2017) W !P O PCT